Award & Recognition NJ Bio, Inc. has repeatedly earned top awards in the CRO space, including multiple World ADC Awards wins and a runner-up recognition in 2025. This demonstrates strong market validation and credibility with potential clients seeking trusted CRO partnerships for antibody-drug conjugate and related biologics programs.

Strategic Acquisitions The majority stake acquisition by Suven Pharma (now Cohance Lifesciences) signals consolidation in the CRO and biotech services sector and may indicate expanded access to capital, larger client networks, and potential cross-sell opportunities for integrated chemistry and biology services across a broader portfolio.

Global Footprint With headquarters in Princeton and additional chemistry facilities in Bristol, PA, plus a subsidiary in Mumbai, India, NJ Bio has a multinational presence that can support global programs, local regulatory support, and nearshoring options for clients seeking geographically diverse CRO capabilities.

Core Expertise NJ Bio specializes in antibody drug conjugates, PROTACs, nucleotide and oligonucleotide synthesis, multi-step organic synthesis, and flow-chemistry based process development. This depth positions the company to target biotech and pharma clients pursuing advanced modalities and scalable manufacturing improvements.

Industry Engagement Active participation in major conferences and events such as BIO International Convention, AACR, TIDES Europe, and World ADC Awards indicates ongoing client outreach and business development momentum. This presence creates opportunities for partnerships, co-development, and lead generation with frontier biopharma programs.